[1] |
XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
|
[2] |
Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease (2017)[J]. J Clin Hepatol, 2017, 33(12): 2270-2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002.
中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33(12): 2270-2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002.
|
[3] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
|
[4] |
CHEN JN, CHEN AP, PAN Q, et al. Influential factors and clinical value of controlled attenuation parameters in the evaluation of hepatic steatosis using FibroScan®[J]. Chin Hepatol, 2016, 21(10): 805-809. DOI: 10.3969/j.issn.1008-1704.2016.10.001.
陈建能, 陈爱萍, 潘勤, 等. FibroScan®实施受控衰减参数检测肝脂肪变的影响因素及应用价值分析[J]. 肝脏, 2016, 21(10): 805-809. DOI: 10.3969/j.issn.1008-1704.2016.10.001.
|
[5] |
CHEN GY, PAN Q, SHEN F, et al. Reproducibility study of Fibroscan for liver controlled attenuator parameters measurement[J]. Chin Hepatol, 2015, 20(11): 855-857. DOI: 10.3969/j.issn.1008-1704.2015.11.005.
陈光榆, 潘勤, 沈峰, 等. Fibroscan检测肝脏受控衰减参数的重复性研究[J]. 肝脏, 2015, 20(11): 855-857. DOI: 10.3969/j.issn.1008-1704.2015.11.005.
|
[6] |
de LÉDINGHEN V, VERGNIOL J, CAPDEPONT M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations[J]. J Hepatol, 2014, 60(5): 1026-1031. DOI: 10.1016/j.jhep.2013.12.018.
|
[7] |
PU K, WANG Y, BAI S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2019, 19(1): 51. DOI: 10.1186/s12876-019-0961-9.
|
[8] |
ANDRADE P, RODRIGUES S, RODRIGUES-PINTO E, et al. Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease[J]. GE Port J Gastroenterol, 2017, 24(4): 161-168. DOI: 10.1159/000453364.
|
[9] |
TONG GD, XING YF, ZHOU XL, et al. Diagnosis and treatment scheme of Ganpi (non-alcoholic steatohepatitis)[J/CD]. Chin J Liver Dis(Electronic Edition), 2021, 13(1): 1-9. DOI: 10.3969/j.issn.1674-7380.2021.01.001.
童光东, 邢宇锋, 周晓玲, 等. 肝癖(非酒精性脂肪性肝炎)诊疗方案[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(1): 1-9. DOI: 10.3969/j.issn.1674-7380.2021.01.001.
|
[10] |
MA YN, LIU JC. Research progress in the noninvasive quantitative diagnosis of hepatic steatosis using controlled attenuation parameters[J]. Chin J Gastroenterol Hepatol, 2020, 29(11): 1309-1312, 1316. DOI: 10.3969/j.issn.1006-5709.2020.11.023.
马亚楠, 刘近春. 受控衰减参数无创定量诊断肝脂肪变性的研究进展[J]. 胃肠病学和肝病学杂志, 2020, 29(11): 1309-1312, 1316. DOI: 10.3969/j.issn.1006-5709.2020.11.023.
|
[11] |
VUPPALANCHI R, SIDDIQUI MS, van NATTA ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease[J]. Hepatology, 2018, 67(1): 134-144. DOI: 10.1002/hep.29489.
|
[12] |
KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66(5): 1022-1030. DOI: 10.1016/j.jhep.2016.12.022.
|
[13] |
WANG YH, ZHANG HO. Clinical research on evaluating nonalcoholic fatty liver and its TCM syndrome type by fat attenuation index[J]. Chin J Integr Tradit West Med Liver Dis, 2017, 27(1): 16-19. DOI: 10.3969/j.issn.1005-0264.2017.01.006.
王玉衡, 张海鸥. 应用脂肪衰减参数评价非酒精性脂肪肝与中医证型关系[J]. 中西医结合肝病杂志, 2017, 27(1): 16-19. DOI: 10.3969/j.issn.1005-0264.2017.01.006.
|
[14] |
ZHANG T, DONG SJ, HAN YJ. Application of fat attenuation parameter to the diagnosis of fatty liver of different Chinese medicine syndromes[J]. Henan Tradit Chin Med, 2016, 36(11): 1940-1942. DOI: 10.16367/j.issn.1003-5028.2016.11.0780.
张婷, 董淑娟, 韩艳俊. 脂肪衰减参数在不同中医证型脂肪肝诊断中的应用[J]. 河南中医, 2016, 36(11): 1940-1942. DOI: 10.16367/j.issn.1003-5028.2016.11.0780.
|
[15] |
LI ZJ, WU PC, ZHOU S. Effect observation on treating nonalcoholic fatty liver with Tiaogan Yunpi Huazhuo decoction and electroacupuncture[J]. J Changchun Univ Chin Med, 2021, 37(1): 103-107. DOI: 10.13463/j.cnki.cczyy.2021.01.028.
李枝锦, 吴平财, 周山. 调肝运脾化浊方联合电针治疗非酒精性脂肪肝[J]. 长春中医药大学学报, 2021, 37(1): 103-107. DOI: 10.13463/j.cnki.cczyy.2021.01.028.
|
[16] |
ZHANG XL, LIU MJ. Study on optimum scheme of establishing rat obesity model based on modern literature[J]. J Changchun Univ Chin Med, 2019, 35(1): 131-135. DOI: 10.13463/j.cnki.cczyy.2019.01.039.
张晓林, 刘明军. 基于现代文献探索大鼠肥胖模型建立的优选方案研究[J]. 长春中医药大学学报, 2019, 35(1): 131-135. DOI: 10.13463/j.cnki.cczyy.2019.01.039.
|
[17] |
ZHU YB, WANG Q, WU CY, et al. Logistic regression analysis on relationships between traditional Chinese medicine constitutional types and overweight or obesity[J]. J Chin Integr Med, 2010, 8(11): 1023-1028. DOI: 10.3736/jcim20101104.
朱燕波, 王琦, 吴承玉, 等. 18805例中国成年人中医体质类型与超重和肥胖关系的Logistic回归分析[J]. 中西医结合学报, 2010, 8(11): 1023-1028. DOI: 10.3736/jcim20101104.
|